Oncology targeted therapy with egSEQ NGS



Personalised diagnostic and precision medicine for cancer patients involves tailoring each patient’s treatment based on the genomic profile of their tumours, in particular the individual’s drug-related genes (Guan et al., 2012).

NGS provides an accurate and cost-effective mean to evaluate the presence of specific mutations in the cancer tissue, enabling the individual to be selected for the targeted therapy. The list of therapies for breast and colorectal cancer with a specific genotype are listed in Tables 1 and 2.

Table 1. Possible therapy options for patients with specific biomarkers.

Biomarker

Possible Therapy

ERBB2 (HER2) gene amplification

​Trastuzumab (Herceptin)

Ado-trastuzumab-emtansine (Kadcyla)

Fam-trastuzumab deruxtecan (Enhertu)

Dertuzumab (Perjeta) Margetuximab (Margenza) (Rugo et al., 2021) (not approved by NICE)

Hormone positive, ERBB2 (HER2) negative

​Palbociclib (Ibrance)

Ribociclib (Kisqali)

Abemaciclib (Verzenio)

Everolimus (Afinitor)

Triple-negative breast cancers

​Talazoparib (Talzenna)

PIK3CA positive gene mutation, ERBB2 (HER2) negative

Alpelisib (Piqray) (FDA approved, NICE not approved)

NTRK1, NTRK2 and NTRK3 fusion-positive

Entrectinib (Rozlytrek)

Larotrectinib (Vitrakvi)

BRCA1 and BRCA2 gene mutations

Olaparib (Lynparza)

Talazoparib (Talzenna)


Table 2. Possible therapy options for patients with specific biomarkers.

Biomarker

Possible Therapy

EGFR gene mutation with normal (wild-type) KRAS gene

Cetuximab (Erbitux)

EGFR gene mutation with normal (wild-type) KRAS and NRAS genes

Panitumumab (Vectibix)

BRAF V600E mutation

Encorafenib (Braftovi) + Cetuximab (Erbitux)

NTRK1, NTRK2 and NTRK3 fusion-positive

Entrectinib (Rozlytrek)

Larotrectinib (Vitrakvi)

Combined with the latest research, our egSEQ library preparation and targeted sequencing solutions are utilised for cancer screening and genomic profiling to provide individual patients with an opportunity for optimal treatment depending on the aspect of their cancer type.


Related Links:

  1. egSEQ Comprehensive Solid Tumours

  2. egSEQ Whole Exome

  3. egSEQ Haematology

  4. Library Preparation

Citations:


Guan, Y. F., Li, G. R., Wang, R. J., Yi, Y. T., Yang, L., Jiang, D., ... & Peng, Y. (2012). Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer. Chinese journal of cancer, 31(10), 463.

Rugo, H. S., Im, S. A., Cardoso, F., Cortés, J., Curigliano, G., Musolino, A., ... & SOPHIA Study Group. (2021). Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA oncology, 7(4), 573-584.


#Oncology #ComprehensiveSolidTumours #Haematology